Yale Technology Spotlight: D2B3
Unlocking the blood brain barrier
A team at Yale has the potential to revolutionize the neurology field with D2B3, a groundbreaking drug delivery technology that temporarily and reversibly opens the BBB.
FOUNDED
February, 2024
Branford, CT
FOUNDERS
Anne Eichmann, PhD, Ensign Professor of Medicine (Cardiovascular Medicine) and Professor of Cellular And Molecular Physiology
Kevin Boyé, PhD, Researcher, Yale School of Medicine
Manuel Mohr, PhD, Blavatnik Fellow, Yale Ventures
TECHNOLOGY
Core Technology: monoclonal antibody that transiently opens the blood brain barrier for drug delivery to the central nervous system
Applications: Broad applications across a variety of brain diseases such as brain tumors, neurodevelopmental and neurodegenerative diseases, Alzheimer’s, brain infections, chronic pain and many more.
In the Founder's Words
Our mission is to revolutionize the treatment of brain diseases by completely changing how we deliver drugs across the blood brain barrier and into the central nervous system." – Manuel Mohr, PhD, CEO, D2B3, Blavatnik Life Science Entrepreneurial Fellow, Yale Ventures
Achievements
- Secured >$500k funding, won several pitch awards including the Alexandria LaunchLabs Innovation Award and the IndieBio New York cohort
- Formed launch team and advisory board including biotech veterans such as Franz Hefti, PhD – former CEO of Prevail therapeutics.
Future Outlook
In the next 6 months, D2B3, Inc. will complete its first non-human primate study assessing safety and efficacy in larger animals. Throughout the next year, D2B3 is scheduled to scale up manufacturing and complete the majority of IND enabling studies to bring it’s first of a kind BBB-opening technology to patients suffering from brain tumors. In parallel, the team will continue to expand its therapeutic pipeline both in house as well as in partnership with pharma companies to extend the reach of existing and new drug assets to the CNS.